Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
(Date:11/24/2014)... N.J. , Nov. 24, 2014  IGI Laboratories, ... based specialty generic pharmaceutical company, today announced ... (ANDA) to the U.S. Food and Drug Administration (FDA), ... in 2014 to seven, with eighteen submissions now pending ... , President and CEO of the Company, commented, "Our ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2
... Bioscience picks Microsoft technology over competitors for its ease ... use, scalability and manufacturing capabilities., ... PURE Bioscience has selected Microsoft Dynamics AX 4.0,to speed ... compliance with the Sarbanes-Oxley Act and with the requirements,of ...
... (Amex:,SVA), a leading provider of vaccines in China, today ... March 31, 2008 at 9:00 a.m. ET to review,the ... financial,results and provide an update on recent corporate developments., ... (USA) or,1-201- 689-8471 (international). A replay of the call ...
... PRINCETON, N.J., March 25 Derma Sciences,Inc. (OTC ... care,products, today announced that MEDIHONEY(TM) Wound & Burn ... subject of several recent,television news health segments., ... University,pilot program that is evaluating MEDIHONEY for wound ...
Cached Biology Technology:Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules 2Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules 3Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules 4Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules 5Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results 2Derma Sciences' MEDIHONEY(TM) Profiled in Several Television News Health Reports 2
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... Carolina State University have found a way to "cage" ... can be activated when exposed to UV light. Their ... and study gene function in localized areas of developing ... are like short snippets of DNA that, when introduced ...
... published online Saturday in the Journal of Geophysical ... Union (AGU), scientists reported the southern Baffin Bay off ... were last effectively measured there in the early 2000s. ... narwhals, medium-sized toothed Arctic whales, during NOAA-sponsored missions in ...
... Washington, DC (October 27, 2010) Recognizing the innovative ... Inventors Competition, a program of Invent Now, today announced ... mice to facilitate drug testing and a way to ... this year,s competition. Alice Chen of the Harvard/MIT ...
Cached Biology News:NOAA: Tagged narwhals track warming near Greenland 2Winners announced in 2010 Collegiate Inventors Competition 2Winners announced in 2010 Collegiate Inventors Competition 3Winners announced in 2010 Collegiate Inventors Competition 4Winners announced in 2010 Collegiate Inventors Competition 5
... Kit, 500 reactions. Prepare circular DNA ... h.Generate microgram quantities of template DNA ... amplified DNA directly for cycle sequencing ... M13 liquid cultures, colonies, plaques, or ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: